CBR1 and hepatocellular carcinoma: Similarly, Y6, an ethylated derivative of EGCG, was also revealed to significantly inhibit the CBR1 expression in hepatoma cells, thus enhancing the efficacy of daunorubicin against HCC (Zhou et al., 2020).